Concourse Financial Group Securities, Inc. Inozyme Pharma, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$4.31 - $6.0 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$4.33 - $7.31 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$4.14 - $7.66 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$2.71 - $4.5 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$4.09 - $7.0 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$4.09 - $7.0 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$4.93 - $6.74 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.3 - $5.73 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.05 - $2.82 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$2.57 - $5.45 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$3.2 - $5.96 $0 - $0
Q1 2022 May 09, 2022	BUY	$3.87 - $7.55 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$5.58 - $11.5 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$11.12 - $19.4 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$15.19 - $21.2 $0 - $0
Q1 2021 May 13, 2021	BUY	$17.77 - $27.9 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$19.95 - $27.55 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$17.54 - $30.2 $0 - $0

Others Institutions Holding INZY

# of Institutions

Shares Held

53M

Call Options Held

3.7K

Put Options Held

5.8K

Adage Capital Partners Gp, L.L.C. Boston, MA

5.67M
Shares

$17 Million
0.05% of portfolio
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA

4.49M
Shares

$13.4 Million
18.53% of portfolio
Sofinnova Investments, Inc. Menlo Park, CA

4.28M
Shares

$12.8 Million
2.12% of portfolio
Eventide Asset Management, LLC Boston, MA

4.13M
Shares

$12.4 Million
0.38% of portfolio
Rock Springs Capital Management LP Baltimore, MD

3.8M
Shares

$11.4 Million
0.68% of portfolio

View Full List

About Inozyme Pharma, Inc.

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $120M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

More about INZY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account